Full Press Release Details
ADC Therapeutics to Participate in May Investor
LAUSANNE, Switzerland, May 4, 2021
- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug
conjugates (ADCs) to treat hematological malignancies and solid tumors, announced today that Chris Martin, Chief Executive Officer, will
participate in a fireside chat at two virtual investor conferences in May.
Details of the events are as follows:
A live webcast of each fireside chat
will be available via the Events & Presentations page in the Investors section of ADC Therapeutics' website, ir.adctherapeutics.com.
A replay of each webcast will be available for approximately 30 days.
About ADC Therapeutics
ADC Therapeutics (NYSE: ADCT) is a commercial-stage
biotechnology company improving the lives of cancer patients with its next-generation, targeted antibody drug conjugates (ADCs). The
Company is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm for patients with hematologic malignancies
ADC Therapeutics' CD19-directed
ADC ZYNLONTA (loncastuximab tesirine-lpyl) is approved by the FDA for the treatment of relapsed or refractory diffuse large B-cell
lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in late-stage clinical trials in combination with other agents.
Cami (camidanlumab tesirine) is being evaluated in a late-stage clinical trial for relapsed or refractory Hodgkin lymphoma and in a Phase
1b clinical trial for various advanced solid tumors. In addition to ZYNLONTA and Cami, the Company has multiple PBD-based ADCs in ongoing
clinical and preclinical development.
ADC Therapeutics is based in Lausanne
(Biop le), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey. For more information, please visit
https://adctherapeutics.com/ and follow the Company on Twitter and LinkedIn.
ZYNLONTA is a trademark of ADC